SEARCH

SEARCH BY CITATION

References

  • 1
    Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 115, 71–85.
  • 2
    Early Breast Cancer Trialists Collaborative Group. The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 1988; 319: 168192.
  • 3
    Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med 1988; 319: 67783.
  • 4
    Nissen-Meyer R, Host H, Kjellgren K, Mansson B, Norin T. Short perioperative versus long-term adjuvant chemotherapy. In: MetzgerU, LargiaderF, SennH, editors. Recent results in cancer research. Heidelberg: Springer-Verlag, 1985: 918.
  • 5
    Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity trial of adjuvant chemotherapy for stage II, node positive breast carcinoma: initial results of CALGB8541. N Engl J Med 1994; 12539.
  • 6
    Misset JL, Gil-Delgado M, Fumoleau P, Chollet P, Belpomme D, Fargeot P, et al. Ten-year results of the French Adjuvant Trial for node positive breast cancer comparing CMF to a combination of Adriamycin, vincristine, cyclophosphamide, and 5-fluorouracil. In: SalmonSE, editor. Adjuvant therapy of cancer VII. Philadelphia: Lippincott, 1993: 17580.
  • 7
    Korzun A, Norton L, Perloff M, Wood W, Carcy R, Rice M, et al. Clinical equivalence despite dosage differences of two schedules of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer [abstract]. Proc Am Soc Clin Oncol 1988; 7: 12.
  • 8
    Moliterni A, Bonadonna G, Valagussa P, Ferraril L, Zambetti M. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991; 9: 112430.
  • 9
    Fisher B, Costantino J, Redmond C, Wickerham DL. Recent information from current NSABP trials of adjuvant therapy for breast cancer. In: SalmonSE, editor. Adjuvant Therapy of Cancer VII. Philadelphia: Lippincott, 1993: 14861.
  • 10
    Carbone PP. Adjuvant therapy of stage II breast cancer. Cancer 1990; 65: 214854.
  • 11
    Chaitchik S, Borovik R, Robinson E, Palti S, Biran S, Brufman G, et al. Adjuvant chemotherapy for stage II breast cancer: CMF vs. alternating CMF-VA [abstract]. Am Soc Clin Oncol 1989; 8: 48.
  • 12
    Levine MN, Gent M, Hryniuk WM, Bramwell V, Abu-Zahra H, De Pauw, et al. A randomized trial comparing 12 weeks with 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 1990; 8: 121725.
  • 13
    Carpenter JT, Velez-Garcia E, Aron BS, Salter M, Stahl DM, Estes N, et al. Prospective randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for breast cancer with positive axillary nodes: a Southeastern Cancer Study Group study [abstract]. Proc Am Soc Clin Oncol 1991; 10: 45.
  • 14
    Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Bowman D, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 148396.
  • 15
    Fisher B, Redmond C, Poisson S, Dimitrov N, Margolese R, Bowman D, et al. Increased benefit from addition of Adriamycin and cyclophosphamide (AC) to tamoxifen (Tarn, T) for positive-node, tam-responsive postmenopausal breast cancer patients: results from NSABP B-16 [abstract]. Proc Am Soc Clin Oncol 1990; 9: 20.
  • 16
    Coombes RC, Bliss JM, Marty M, Wils J, Amadori D, Beretta Q, et al. A randomized trial comparing adjuvant FEC with CMF in premenopausal patients with node positive resectable breast cancer [abstract]. Proc Am Soc Clin Oncol 1991; 10: 41.
  • 17
    Henderson IC. The nature of benefit. In: Adjuvant therapy of breast cancer. Boston: Kluwer Academic, 1992: 5768.
  • 18
    Simes RJ, Margrie SJ. Patient preferences for adjuvant chemotherapy in breast cancer: report #8901. Sydney, Australia: NHMRC Clinical Trials Center, 1991
  • 19
    Muss HB, Thor A, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erb B-2 expression and S-Phase activity, predict response to adjuvant therapy in women with node positive early breast cancer: a comparison study of the Cancer and Acute Leukemia Group B (CALCB). N Engl J Med 1994; 330: 12606.
  • 20
    Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599605.
  • 21
    Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erb B-2 expression in breast cancer. J Clin Oncol 1992; 10: 104956.
  • 22
    Dimitrov N, Anderson S, Fisher B, Redmond C, Wickerham DL, Pugh R, et al. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): findings from NSABP B-22. Proc Am Soc Clin Oncol. In press.
  • 23
    Robert NJ, Gray R, Gelber RD, Goldhirsch A, Abeloff M, Tormey DC. Node positive (N+) breast cancer: which patients (Pts) are at high risk [abstract]? Proc Am Soc Clin Oncol 1991; 10: 59.
  • 24
    Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 113243.
  • 25
    National Institutes of Health Consensus Development Panel. Consensus statement: treatment of early-stage breast cancer. J Natl Cancer Inst Monogr 1992; 11: 15.
  • 26
    Henderson IC. Adjuvant systemic therapy of early breast cancer. In: HarrisJR, HellmanS, HendersonIC, et al. editors. Breast diseases. 2nd ed. Philadelphia: Lippincott, 1991: 42786.